Introduction
Xenon Pharmaceuticals (XENE), a Canadian biotech, is quietly developing a pipeline of promising orphan/CNS assets. 2020 is likely to see two phase 2 readouts as well as two trial initiations (one pivotal). XEN1101, a novel Kv7 Potassium Channel Modulator, is being trialed in 300 adult focal epileptic patients with phase 2 data expected in 2H. One can reasonably ascribe a high degree of confidence in phase 2 success based phase 1b data in healthy volunteers and the mechanism of action's past. XEN007 is being developed for childhood absence epilepsy [CAE]. The drug